Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-11-18. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subject hasthe subjectmetastaticsubjects withradiation
  Phrases that lowered it: days beforemmevaluateovarianweeks before
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 39.6% (raises risk) · Drug's FDA history
• Responsible party: sponsor investigator (raises risk) · Design
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 1 (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports marked serious: 71.7% (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 9893 (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer NCT03542877 · started 2018 · scored riskier than 77% of active trials completed
• A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer NCT03316586 · started 2017 · scored riskier than 82% of active trials completed
• Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors NCT03945773 · started 2020 · scored riskier than 86% of active trials completed
• Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors NCT05038839 · started 2022 · scored riskier than 70% of active trials completed
• Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy NCT04868773 · started 2021 · scored riskier than 56% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.